Theravance Biopharma, Inc.
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for maintenance of chronic obstructive pulmonary disease (COPD); the company and Viatris share US commercialization, with… From the company’s description.
Over the twelve months to Jun 30, 2026, Theravance Biopharma, Inc. reported revenue of $104.31M, up 35.1% from a year earlier, and net income of $53.81M. Its operating margin was −4.0%, and operations generated $53.74M in cash. In fiscal 2025, it reported revenue of $107.46M, up 66.9% from fiscal 2024, and net income of $105.89M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Theravance Biopharma, Inc. does
In the company’s own words
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for maintenance of chronic obstructive pulmonary disease (COPD); the company and Viatris share US commercialization, with Viatris leading sales and Theravance Biopharma co-promoting. In 2025, YUPELRI generated $266.6 million in total net sales. The company has one core commercial product rather than reportable business segments described here, and its research and development operations are being wound down following the failure of a Phase 3 study of ampreloxetine, an investigational treatment for neurogenic orthostatic hypotension in multiple system atrophy. Theravance Biopharma also sold its remaining royalty interest in TRELEGY in 2025, retaining eligibility for certain milestone payments. Its website is www.theravance.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- GEORGE TOWN, GRAND CAYMAN, CA
- Fiscal year end
- December
- CIK
- 1583107
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Theravance Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Theravance Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Theravance Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Theravance Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Theravance Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”